Our Pipeline

Focused on making an impact in the lives of people living with cancer

Cyclacel’s pipeline of medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience of oral administration. We have retained worldwide rights for all of our prescription candidates, excluding in Japan for sapacitabine.

*Phase 2 in planning. AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; CLL, chronic lymphocytic leukemia; DDR, DNA damage response; IV, intravenous; MDS, myelodysplastic syndrome; MOA, mechanism of action; PLK, polo-like kinase; PoC, proof of concept ; R/R, relapsed or refractory. 140-01 part 1 IV in R/R AML/MDS 065-102 streamlined multicohort oral study to PoC in leukemias/MDS Streamlined multicohort oral study to PoC in solid tumors* Streamlined multicohort oral study to PoC in leukemias/MDS* 065-101 streamlined multicohort oral study to PoC in solid tumors Rx Candidate & MOA Fadraciclib Oral CYC140 Oral Sapacitabine Oral Phase 1 Phase 1- 2 Phase 3 CDK2 and CDK9 PLK1 DDR 682-11 sapacitabine + venetoclax in R/R AML/MDS 065-01 parts 1, 2 IV part 3 in oral solid tumors 065-02 IV + venetoclax in CLL 065-03 IV + venetocloax in AML/MDS

Our Clinical Trials

icon - Fadraciclib

Fadraciclib is a highly selective inhibitor of CDK2 and CDK9 currently being evaluated in midstage clinical trials in both patients with solid cancers and hematologic malignancies.

icon - CYC140
CYC140 is a highly selective PLK-centric inhibitor currently in Phase 1 studies. Midstage clinical trials in both patients with solid cancers and hematologic malignancies are being planned.
icon - Sapacitabine

Sapacitabine (CYC682) is an orally available nucleoside analogue with a unique DDR mechanism.

Interested in Learning More About Cyclacel?

woman and man on computer

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.